Cardiotoxicity Following Cancer Treatment. - Wikidata - awgldk - TriplyDB

Cardiotoxicity Following Cancer Treatment.

Cardiotoxicity Following Cancer Treatment.

http://www.wikidata.org/entity/Q37663263

about

Synergistic apoptotic effects of apigenin TPGS liposomes and tyroservatide: implications for effective treatment of lung cancer.Cardiotoxicity of Anticancer Therapeutics.

P2860

Q41096219-9BA59CFE-C151-4096-8167-28261BF19DA6 Q50326869-E8EB31D6-C49D-4A9D-BAF7-529A805F3A8A

P2860

Cardiotoxicity Following Cancer Treatment.

http://www.wikidata.org/entity/Q37663263

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on January 2017

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Cardiotoxicity Following Cancer Treatment.

@en

Cardiotoxicity Following Cancer Treatment.

@nl

type

label

Cardiotoxicity Following Cancer Treatment.

@en

Cardiotoxicity Following Cancer Treatment.

@nl

prefLabel

Cardiotoxicity Following Cancer Treatment.

@en

Cardiotoxicity Following Cancer Treatment.

@nl

P1433

Q37663263-91AC249A-346D-4AB1-AD18-C00A5A2045FC

P1476

Q37663263-EDFAD0C8-DF49-45F5-898C-1D5F619B81A7

P2093

Q37663263-276D4E34-29F3-4F53-827A-D4292B2F7E8D

Q37663263-2D987E11-231A-4AE9-ADC1-96DCB107413F

Q37663263-8C79190D-0B0E-4FD2-9618-FB0D677CCA17

Q37663263-A458CD46-4096-420E-8130-D7988C0F6628

P275

Q37663263-ACF0D733-3273-4255-8B3D-93626EBF5575

P2860

Q37663263-05266DF8-1623-489E-B090-E33985F07CAC

Q37663263-05E0D9E5-E51B-4EA9-89FA-BBCDEAC0D70E

Q37663263-07EE47EE-34A6-48ED-BF69-C104CAFFB8D6

Q37663263-13375F2F-1B55-4D5B-87B4-DAD13201EB46

Q37663263-13E9B482-F047-47B8-B697-5AC37F0DD837

Q37663263-1E49C0C2-C2AC-4333-A6E6-2D3B3350D10A

Q37663263-2180BCB8-CB5A-46C5-A77F-A4AE81533CA6

Q37663263-23A75824-923D-46F8-A3EF-FAF976676F69

Q37663263-2848D53F-5995-404F-B1F7-4813146B8AA7

Q37663263-2A9A1CD1-9D1E-4F1A-8687-8C55854A4357

P304

Q37663263-3A5CF8E3-55F7-4030-BEBA-2F50D3801A34

P31

Q37663263-8F74367F-CFBA-4A18-A3EB-59FA62ECB9C9

Q37663263-E9405787-3094-4175-AAF7-867356B0DAFE

P433

Q37663263-F2C9650A-C16A-4FC8-B0CB-AF9B5A31D501

P478

Q37663263-824C0604-71A1-4595-B8D2-19AFD08C9D25

P5008

Q37663263-33F89761-0BD5-4528-BD04-8CB3502150F8

P577

Q37663263-CE2BFBFE-C12A-4464-84F6-395FACA40525

P698

Q37663263-0869A195-9584-48E5-8109-A23CB42BE808

P921

Q37663263-210D169D-3CAE-4E7C-9FD7-948C8FF14072

Q37663263-4540E044-1B21-473F-A902-6F67606CA52D

P932

Q37663263-6126E371-F96A-46C0-9EBC-9E60C3413BC0

P1433

Ulster Medical Journal

P1476

Cardiotoxicity Following Cancer Treatment.

@en

P2093

A R Lyon

http://www.w3.org/2001/XMLSchema#string

G G Hanna

http://www.w3.org/2001/XMLSchema#string

G M Walls

http://www.w3.org/2001/XMLSchema#string

M T Harbinson

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International

P2860

Cardioprotective interventions for cancer patients receiving anthracyclines

Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Cardiac risk in the treatment of breast cancer: assessment and management.

5-fluorouracil: mechanisms of action and clinical strategies

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.

Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials.

Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy.

P304

3-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

86

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2017-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28298705

http://www.w3.org/2001/XMLSchema#string

P921

P932

5324172

http://www.w3.org/2001/XMLSchema#string